Navigation Links
CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Date:8/14/2008

- Awards recognize innovative biopharmaceutical drugs and devices that have

made a deep impact on the quality of human life -

PALO ALTO, Calif., Aug. 14 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that its chronic angina therapy Ranexa(R) (ranolazine extended-releases tablets) has been selected as a finalist for the prestigious Prix Galien USA 2008 award which honors the best pharmaceutical agent and best biotechnology product of the year. Winners will be announced on September 24, 2008 in New York.

"Being named a finalist for the Prix Galien USA awards is a great honor. We congratulate the dedicated employees, researchers and physicians who make it possible for this important medicine to help patients every day," said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics.

The Prix Galien USA Awards committee of 11, including seven Nobel Laureates, recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines that improve the human condition, and is considered the industry's highest accolade for pharmaceutical research and development.

About Ranexa(R)

In the United Sates, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs. In Europe, ranolazine is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company pri
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
2. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
5. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
8. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
9. CV Therapeutics Reports 2008 Second Quarter Financial Results
10. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
11. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 WriteResult, LLC – a premier ... again shown superiority when it comes to meeting the ... ePRO portion of their most recent study closeout on-time ... chose WriteResult’s digital writing platform to collect Patient Reported ... to complete drew data from a number of assessments ...
(Date:8/26/2014)... and Bellingham, WA (PRWEB) August 26, 2014 ... engineering, visions for next-generation wearable technology, and inspiration ... numerous highlights at this year’s brighter, busier ... Diego, California, Convention Center. More than 4,400 international ... attended conferences, courses, an exhibition, and industry sessions ...
(Date:8/26/2014)... A new argument has just been added to ... its pedestal as the next big thing in ... as MX2 materials. An international collaboration of researchers ... of Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley ... ultrafast charge transfer in photo-excited MX2 materials. The ...
(Date:8/26/2014)... ARBOR, Mich. , Aug. 26, 2014 /PRNewswire/ ... the development of breakthrough oral medicines to treat ... of immune modulation, today announced the appointment of ... the company,s scientific advisory board.  Dr. Singh will ... insight to advance Lycera,s multiple ongoing research programs ...
Breaking Biology Technology:A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4Competition for graphene 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 3
... Logical Therapeutics, Inc., a,biotechnology company focused ... associated with poorly controlled inflammation, announced today,the ... controlled multi-dose,safety and pharmacokinetics study of LT-NS001, ... was conducted from December, 2007,through July, 2008 ...
... Pharmacology Space and Drug Target Knowledge Databases ... Related to Nuclear Receptors and Proteases, ... provider of,knowledge management solutions that accelerate life sciences discovery,announced ... The new offerings include knowledge databases for the important,drug ...
... Board: LFVN), the maker of Protandim(R), the only product,clinically ... announced,that the company,s President & CEO, David Brown, is ... The interview gives viewers an overview of the ... To view the clip in ...
Cached Biology Technology:Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug 2Aureus Pharma Releases New Unified Knowledge Database 2[video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.net's 3-Minute Press Show 2
(Date:8/27/2014)... trans-fats have largely succeeded in sidelining the use ... for its potential contributions to Americans, health conditions. ... the best way to assuage the nation,s insatiable ... Chemical & Engineering News (C&EN), the weekly ... In the article, Stephen Ritter, a senior correspondent ...
(Date:8/27/2014)... As of seven hours ago the Happy Camp Complex ... Northern California, the July complex had consumed 35,530 as ... seventeen fires on the Happy Camp Ranger District of ... the area on August 11, 2014. All but three ... following is a list of contained fires and their ...
(Date:8/26/2014)... St. Louis have developed algorithms to identify weak spots ... breaking. The technology, which needs to be refined before ... pinpoint minor strains and tiny injuries in the body,s ... is available online Aug. 27 in the Journal ... at the nexus of the physical and life sciences. ...
Breaking Biology News(10 mins):Happy Camp and July Fire Complexes in California 2New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3
... as being in perpetual conflict, but a new study by ... major research universities see religion and science as requiring distinct ... of life, ways of understanding reality, origins of Earth and ... science as being at odds and even in irreconcilable conflict," ...
... in German . Jean-Baptiste Lamarck would ... his belief that acquired traits can be passed on to ... of transformation went onto the ash heap of history. But ... can after all leave traces in the genomes of animals ...
... from the medical and research communities held high-level discussions ... Office of Naval Research (ONR), Sept. 16. "ONR,s ... with the Marine Corps component because of the physical ... Research Rear Adm. Nevin Carr. "This meeting of the ...
Cached Biology News:Science and religion do mix 2Science and religion do mix 3Epigenetic changes don't last 2Epigenetic changes don't last 3Epigenetic changes don't last 4ONR officials meet with Navy Surgeon General to coordinate medical research 2
... The Fluorescence Test Plate consists of an ... with Inert Organic Fluorescent Compounds embedded in ... used on BioTeks FLx800 and Synergy Multi-Detection ... for GLP compliance while reducing the need ...
... line is a Greenough stereomicroscope designed for the ... available with a choice of a large working ... (N2GG). This microscope can be easily connected to ... the same time giving you ultimate flexibility. Available ...
... MATra-si Reagent optimized for siRNA applications, contains ... with the nucleic acid of interest. Exploiting ... is then rapidly drawn towards and delivered ... transfection. MATra-si Reagent can be used for ...
...
Biology Products: